HK Stock Market Move | Game stocks lead gains as "Phantom Blade Zero" ignites market sentiment; game license approvals remain at a high level.
Game stocks lead gains. As of press time, NetEase (09999) rose 9.23% to HK$199.9; Bilibili-W (09626) rose 7.08% to HK$114.9; XD Inc. (02400) rose 6.74% to HK$44.98; Tencent Holdings (00700) rose 6.72% to HK$428.6; Kingsoft (03888) rose 4.82% to HK$25.66.
Game stocks lead gains. As of press time, NTES (09999) rose 9.23% to HK$199.9; BILIBILI-W (09626) rose 7.08% to HK$114.9; XD INC (02400) rose 6.74% to HK$44.98; TENCENT (00700) rose 6.72% to HK$428.6; KINGSOFT (03888) rose 4.82% to HK$25.66.
On the news front, on November 2, the official announcement for the domestic AAA game "Phantom Blade Zero" stated that sales exceeded 4 million copies within 72 hours of release. Based on the standard edition price of RMB268, its global sales revenue has surpassed RMB1 billion. It is reported that in July this year, among the domestic online game approval information released by the National Press and Publication Administration, S-Game's "Phantom Blade Zero" was included, making it one of the most closely watched game products to obtain a license that month.
It is worth noting that the official website of the National Press and Publication Administration shows that a total of 195 online game licenses were approved in October. According to statistics, as of now, the number of games that have obtained licenses in 2026 has reached 1,766, with the total clearly increasing compared with the same period last year. Guotai Haitong pointed out that the regular, high-volume issuance of game licenses directly confirms that the current game regulatory environment continues to be relaxed, and the policy side has a clear encouraging attitude toward content innovation and global expansion in the game industry. The core driver of upward performance for game companies comes from hit products.
Related Articles
.png)
Ningbo Menovo Pharmaceutical (603538.SH): Xuancheng Ningbo Menovo Pharmaceutical's Tildipirosin API passes FDA on-site inspection for the first time

US IPO Preview | HEACU: A $100 Million Trust "Safety Cushion" and Zero-Debt M&A Confidence How to Leverage SPACs to Capture Hard-Tech Dividends?

Hefei Conver Holding (603409.SH): Actual controller proposes share buyback of RMB20 million to RMB40 million.
Ningbo Menovo Pharmaceutical (603538.SH): Xuancheng Ningbo Menovo Pharmaceutical's Tildipirosin API passes FDA on-site inspection for the first time
.png)
US IPO Preview | HEACU: A $100 Million Trust "Safety Cushion" and Zero-Debt M&A Confidence How to Leverage SPACs to Capture Hard-Tech Dividends?

Hefei Conver Holding (603409.SH): Actual controller proposes share buyback of RMB20 million to RMB40 million.






